Trading Signals: TNXP Stock Price Prediction and Forecast (Fri. Feb. 3, 2012 - Fri. May. 13, 2022)(Tonix Pharmaceuticals)
| TNXP latest price $0.2369 (-6.07%) ($0.2369 - $0.2369) on Fri. Jan. 21, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.63% (three month average) | RSI | 22 | Latest Price | $0.2369(-6.07%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TNXP declines -3.7% a day on average for past five trading days. | Weekly Trend | TNXP declines -14.8% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TNXP advance at 0% a week (0% probability) ACES(51%) XBI(50%) BLOK(49%) BOTZ(49%) URA(49%) | Factors Impacting TNXP price | TNXP will decline at least -2.315% in a week (0% probabilities). VIXM(-44%) VXX(-36%) UUP(-18%) UNG(-13%) TLT(-13%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.315% (StdDev 4.63%) | Hourly BBV | -1.6 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-25.68(-10940.02%) | Resistance Level | $0.33 | 5 Day Moving Average | $0.26(-8.88%) | 10 Day Moving Average | $0.29(-18.31%) | 20 Day Moving Average | $0.33(-28.21%) | To recent high | -59.8% | To recent low | 0% | Market Cap | $63m | | | | Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.July 16, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it has entered into a research collaboration and option agreement with Columbia University focused on studying the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic. The research collaboration will focus on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19 at the cellular level including human monoclonal antibodies and anti-idiotypes. The research is designed to fill in important gaps in understanding the detailed immune responses to COVID-19, and to provide a foundation upon which to target vaccines and therapeutics to appropriate individuals by precision medicine. |